0      0

JL1120ES - JL1120ES: Long-term efficacy, safety and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC

‐ Oct 30, 2023 10:00am

Full author listing Pilar Garrido,1 Nicolas Girard,2 Byoung Chul Cho,3 Joshua K Sabari,4 Alexander I Spira,5 Rachel E Sanborn,6 Koichi Goto,7 James Chih-Hsin Yang,8 Joshua C Curtin,9 Xuesong Lyu,10 Andy He,11 James Penton,12 Joanne Edwards,12 Grace Low,13 Karen Xia,9 Marc Chioda,9 Meena Thayu,9 Roland E Knoblauch,9 Parthiv Mahadevia,9 Natasha B Leighl14

1University Hospital Ramón y Cajal, Madrid, Spain; 2Institut Curie, Paris, France; 3Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; 4NYU Langone Health, New York, NY, USA; 5Virginia Health Specialists, Fairfax, VA, USA; 6Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA; 7National Cancer Center Hospital East, Kashiwa, Japan; 8National Taiwan University Cancer Center, Taipei, Taiwan; 9Janssen R&D, Spring House, PA, USA; 10Janssen R&D, Shanghai, China; 11Janssen Scientific Affairs, LLC, Horsham, PA, USA; 12Janssen EMEA, High Wycombe, UK; 13Janssen Asia-Pacific, Singapore; 14Princess Margaret Cancer Centre, Toronto, ON, Canada

Pilar Garrido, MD, PhD

Nicolas Girard, MD

Byoung Chul Cho, MD PhD

Joshua K Sabari, MD

Alexander I Spira, MD, PhD, FACP

Rachel E Sanborn, MD

Koichi Goto, MD PhD

James Chih-Hsin Yang, MD PhD

Joshua C Curtin, PhD

Xuesong Lyu, PhD

Andy He, PharmD

James Penton, MB

Joanne Edwards, BPharm

Grace Low, PhD

Karen Xia, PhD

Marc Chioda, PharmD

Meena Thayu, MD, MSCE

Roland E Knoblauch, MD, PhD

Parthiv Mahadevia, MD, MPH

Natasha B Leighl, MD, MMSc, FRCPC, FASCO


You must be logged in and own this session in order to post comments.